You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

LOVAZA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lovaza patents expire, and when can generic versions of Lovaza launch?

Lovaza is a drug marketed by Woodward and is included in one NDA.

The generic ingredient in LOVAZA is omega-3-acid ethyl esters. There are thirteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the omega-3-acid ethyl esters profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOVAZA?
  • What are the global sales for LOVAZA?
  • What is Average Wholesale Price for LOVAZA?
Drug patent expirations by year for LOVAZA
Drug Prices for LOVAZA

See drug prices for LOVAZA

Drug Sales Revenue Trends for LOVAZA

See drug sales revenues for LOVAZA

Recent Clinical Trials for LOVAZA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Prisma Health-MidlandsPhase 2/Phase 3
H. Lee Moffitt Cancer Center and Research InstitutePhase 2
James and Esther King Biomedical Research ProgramPhase 2

See all LOVAZA clinical trials

Paragraph IV (Patent) Challenges for LOVAZA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
LOVAZA Capsules omega-3-acid ethyl esters 1 g 021654 3 2008-11-10

US Patents and Regulatory Information for LOVAZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Woodward LOVAZA omega-3-acid ethyl esters CAPSULE;ORAL 021654-001 Nov 10, 2004 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LOVAZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Woodward LOVAZA omega-3-acid ethyl esters CAPSULE;ORAL 021654-001 Nov 10, 2004 ⤷  Sign Up ⤷  Sign Up
Woodward LOVAZA omega-3-acid ethyl esters CAPSULE;ORAL 021654-001 Nov 10, 2004 ⤷  Sign Up ⤷  Sign Up
Woodward LOVAZA omega-3-acid ethyl esters CAPSULE;ORAL 021654-001 Nov 10, 2004 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LOVAZA

See the table below for patents covering LOVAZA around the world.

Country Patent Number Title Estimated Expiration
Austria 453701 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2004007655 ⤷  Sign Up
Denmark 173371 ⤷  Sign Up
Sweden 0202188 ⤷  Sign Up
Denmark 2295529 ⤷  Sign Up
Australia 2003249109 A PROCESS FOR DECREASING THE AMOUNT OF CHOLESTEROL IN A MARINE OIL USING A VOLATILE WORKING FLUID ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.